The burden of RSV-associated illness in children aged < 5 years, South Africa, 2011 to 2016

Abstract Background Vaccines and monoclonal antibodies to protect the very young infant against the respiratory syncytial virus (RSV)-associated illness are effective for limited time periods. We aimed to estimate age-specific burden to guide implementation strategies and cost-effectiveness analyses...

Full description

Bibliographic Details

Published in:	BMC Medicine
Main Authors:	Jocelyn Moyes, Stefano Tempia, Sibongile Walaza, Meredith L. McMorrow, Florette Treurnicht, Nicole Wolter, Anne von Gottberg, Kathleen Kahn, Adam L. Cohen, Halima Dawood, Ebrahim Variava, Cheryl Cohen
Format:	Article
Language:	English
Published:	BMC 2023-04-01
Subjects:	Burden Respiratory syncytial virus Children Respiratory illness
Online Access:	https://doi.org/10.1186/s12916-023-02853-3